Karl-Erik Andersson to Thiazoles
This is a "connection" page, showing publications Karl-Erik Andersson has written about Thiazoles.
Connection Strength
2.113
-
Andersson KE. Pharmacology: Cardiovascular effects of mirabegron. Nat Rev Urol. 2017 10; 14(10):587-588.
Score: 0.520
-
Andersson KE. ß3-receptor agonists for overactive bladder--new frontier or more of the same? Curr Urol Rep. 2013 Oct; 14(5):435-41.
Score: 0.401
-
Sawada N, Nomiya M, Hood B, Koslov D, Zarifpour M, Andersson KE. Protective effect of a ß3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol. 2013 Oct; 64(4):664-71.
Score: 0.394
-
Hood B, Andersson KE. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Int J Urol. 2013 Jan; 20(1):21-7.
Score: 0.375
-
Kallner HK, Elmér C, Andersson KE, Altman D. Hormonal influence on the effect of mirabegron treatment for overactive bladder. Menopause. 2016 12; 23(12):1303-1306.
Score: 0.125
-
Andersson KE. The use of pharmacotherapy for male patients with urgency and stress incontinence. Curr Opin Urol. 2014 Nov; 24(6):571-7.
Score: 0.108
-
Andersson KE, Martin N, Nitti V. Selective ß3-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013 Oct; 190(4):1173-80.
Score: 0.096
-
Svalø J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P. The novel ß3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol. 2013 Jan 15; 699(1-3):101-5.
Score: 0.095